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Abstract 
The present study deals with the bioactivity assessment of 5,11,17,28-tetrakismorpholinomethyl-
25,26,27,28-tetrahydroxycalix[4]arene  (3)  against a  variety  of  microorganisms  including  Gram 
Positive;  Staphylococcus  albus  ATCC  10231,  Streptococcus  viridans  ATCC  12392,  Gram 
Negative: Bacillus procynous ATCC 51189, Enterobacter aerogenes ATCC 13048, Klebsiella 
aerogenous ATCC 10031, Escherichia coli ATCC 8739, Sallmonella ATCC 6017 and Fungi: 
Aspergillus Niger ATCC 16404, Aspergillus fumagatus ATCC 90906, Penicillium ATCC 32333. 
The  antimicrobial  activity  was  found  by  using  a  modified  disc  diffusion  method.  All 
microorganisms were obtained from the American Type Culture Collection (ATCC) and selective 
agar media were employed for the growth of microbial strains. Results show that all the tested 
microorganisms are highly susceptible to compound 3. The MIC of 4 ￿g/￿L and 8 ￿g/￿L was 
determined  against  most  of  the  bacterial  and  fungal  strains.  The  bioactivity  of  3  could  be  a 
valuable addition in therapeutic index. 
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Introduction 
 
Since  decades  consistent  increasing  infectious 
diseases  and  emergence  of  antibiotic  drug 
resistance have enhanced the efforts to synthesize 
and  assess  new  compounds  for  bioactivity.  The 
parent  compounds  selected  for  synthesis  usually 
are those which contain properties of known safety 
and probable efficacy against microorganisms. The 
calixarenes,  a  versatile  class  of  synthetic 
macrocycles has attracted most of the researchers 
working in a wide range of fields. On the basis of 
their nontoxic nature,   calixarenes have extensive 
applications  in  the  biological  and  pharmaceutical 
area [1-3], and are considered in the assessment of 
antimicrobial  activities;  though,  most  of  the 
calixarene components have been reported for their 
efficacy  against  few  microorganism  species 
including bacteria, fungi and viruses [4-8]. On the 
other hand, safety profile reported by Perret F. et 
al.  indicated  calixarenes  as  inert  substances  like 
glucose, but incidence of slight toxicity was found 
with  sulfonate  derivatives  of  calix[4]arene 
compounds [9]. 
 
Previous  researches  have  reported  that 
morpholine  derivatives  possessed  antimicrobial 
activities [10-13]. The mode of action recorded for 
some  of  the  compounds  was  targeting  through 
enzyme  pathway  in  fungi,  therefore  used  as 
fungicide in agriculture fields [14]. As per Material 
Safety Data Sheet (MSDS), no complete  data on 
morpholine  toxicity  is  available  however;  it  has 
been  preferred  in  synthesis  and  development  of 
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new drugs. Thus, in view of these reports and our 
previous  expertise  [15-18]  we  have  synthesized 
5,11,17,28-tetrakismorpholinomethyl-25,26,27,28-
tetrahydroxycalix[4]arene  (3),  a  macromolecule 
based on calixarene and morpholine units in order 
to  explore  their  collective  nature  toward  the 
microorganisms. 
 
Material and Methods 
Apparatus 
 
  Melting  points  were  determined  on  a 
Gallenkamp  apparatus  (UK)  in  a  sealed  glass 
capillary tube and are uncorrected. FT-IR spectra 
were  recorded  on  a  Thermo  Nicollet  AVATAR 
5700 FT-IR spectrometer using KBr pellets in the 
spectral range 4,000-400. Elemental analyses were 
performed using a CHNS instrument model Flash 
EA 1112 elemental analyzer. Analytical TLC was 
performed  on  precoated  silica  gel  plates  (SiO2, 
Merck PF254). 
 
Synthesis and characterization  
 
  5,11,17,28-tetrakismorpholinomethyl-
25,26,27,28-tetrahydroxycalix[4]arene  (3)  was 
synthesized  according  to  the  reported  methods 
[19￿21] as depicted in Fig. 1. Characterization of 
the  compounds  was  made  by  various  techniques 
such as, melting point, TLC, FT-IR, and elemental 
analysis, which confirm the structure and purity of 
the compounds. 
 
 
 
 
 
 
 
Figure  1.  5,11,17,28-tetrakis(morpholinomethyl)-25,26,27,28-
tetrahydroxycalix[4]arene (3). 
 
Microbiological study 
 
Antimicrobial  activity  of  the  test 
compound 3 (Figure 1) was carried out in vitro by 
using modified Kirby-Bauer disc diffusion method 
[22]. The antibacterial and antifungal activity was 
determined against variety of microorganisms from 
the  American  Type  Culture  Collection  (ATCC). 
The  selective  agar  media  were  employed  for  the 
growth  of  microorganism species  including  gram 
positive, gram negative and fungus. Table 1 shows 
distribution of culture strains (ATCC) and types of 
media  obtained  from  Baltimore  Biology  Labs 
(BBL)  USA,  Oxoid  AG  Switzerland  and  Merck 
Frankfurter Germany. All the culture media were 
prepared and used according to the  manufacturer 
guidelines. 
 
Table 1. Distribution of culture strains and media. 
Culture Strains  Media  
Gram Positive 
Staphylococcus albus ATCC 
10231 
Streptococcus viridans ATCC 
12392 
 
Tryptic soya agar (BBL) 
Gram Negative 
Bacillus procynous ATCC 51189 
 
Tryptic soya agar (OXOID) 
Enterobacter aerogenes ATCC 
13048 
Cetrimide agar base (MERCK) 
Klebsiella aerogenous ATCC 
10031 
Lactose broth (MERCK) 
Escherichia coli ATCC 8739 
Sallmonella ATCC 6017 
 
Violet red bile dextrose agar 
(OXOID) 
Fungus 
Aspergillus Niger ATCC 16404 
Aspergillus fumagatus ATCC 
90906 
Penicillium ATCC 32333 
 
Sabourand dextrose agar 
(MERCK) 
 
Bioactivity assay 
 
Ten serial  dilutions  of the  compound  (3) 
yielded the concentrations of 2, 4, 8, 12, 16, 20, 24, 
28,  32  and  36  ￿g/￿L  in  double  distilled  water. 
Filter  paper  discs  (Whatmans￿,  no.  3)  of  6  mm 
diameter  were  impregnated  with  5  ￿L  of  each 
dilution prepared. The paper discs were allowed to 
dry completely at room temperature under sterile 
conditions and stored appropriately until used. The 
discs were placed on to bacterial and fungal agar 
plates  seeded  by  streaking  plate  technique  and 
were incubated at 37 ”C for 24 hours and 48 hours 
respectively.  Simultaneously,  negative  control 
discs  incubated  were  prepared  using  the  same 
solvent  employed to  dissolve the test compound. 
After incubation period the antimicrobial activity 
was  examined  by  measuring  the  diameter  of 
inhibition  zone  in  mm  against  each  strain  of 
microorganisms. Tests were performed in triplicate 
as suggested by Vanden Berghe 1991 [23]. The in 
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quantitatively  assessed  by  determining  the  MIC 
level;  the  lowest  concentration  of  the  substance 
that results in inhibition of macroscopic microbial 
growth after incubation time.  
 
Results and Discussion 
 
Primarily, the bioactivity assessment of the 
compound  3  was  carried  out  by  inhibition  of 
growth  against  bacterial  and  fungal  strains  and 
activity  was presented according to the four step 
criterion.  In  this  criterion,  inhibition  zone 
diameters such as 9-11 mm, 7-9 mm, 5-7 mm and 
below 5 mm were considered as very high activity 
(+++), high activity (++), relatively  high activity 
(+) and  no antimicrobial activity (-), respectively. 
(Table 2) shows that compound 3  has very  high 
antibacterial activity against two gram positive and 
four  gram  negative  bacteria  and  high  activity 
against  rest  of  the  selected  bacteria  and  fungus 
whereas;  no  zone  of  inhibition  was  originated 
around control. The compound 3 has been found 
significantly  active  against  bacterial  and  fungal 
strains. 
 
Table  2.  Primary  screening  of  bioactivity  of  the  tested    
compound 3. 
 
Microbial Strains   Zone of 
Inhibition 
(mm) 
Antibacterial 
Activity 
Gram Positive 
Staphylococcus albus ATCC 10231 
 
9.4 
 
+++ 
Streptococcus viridans ATCC 12392  9.6  +++ 
 
Gram Negative 
Bacillus procynous ATCC 51189 
 
 
10.5 
 
 
+++ 
Enterobacter aerogenes ATCC 13048  11.2  +++ 
Klebsiella aerogenous ATCC 10031  10.6  +++ 
Escherichia coli ATCC 8739  7.2  ++ 
Sallmonella ATCC 6017  11.9  +++ 
 
Fungus 
Aspergillus Niger ATCC 16404 
 
 
7.8 
 
 
++ 
Aspergillus fumagatus ATCC 90906  7.8  ++ 
Penicillium ATCC 32333  9.6  +++ 
Control  0.0  - 
 
The  in  vitro  quantitative  activity  of 
compound  3  was  assessed  with  determination  of 
minimum inhibitory concentration (MIC) values. It 
showed  antibacterial  activity  against  Gram-
positive,  Staphylococcus  albus  with  MIC  level 
equal  to  16  ￿g/￿L,  while  against  Streptococcus 
viridians,  it  appeared  more  sensitive  and  found 
inhibited  at  MIC  4  ￿g/￿L.  Similarly,  zone 
inhibition  diameter  was  larger  at  lowest 
concentration  (MIC  4  ￿g/￿L)  among  the  Gram-
negative  bacteria,  i.e.  Bacillus  procynous, 
Klebsiella  aerogenous,  Escherichia  coli, 
Sallmonella  than  Enterobacter  aerogenes  with 
MIC  level  8  ￿g/￿L.  The  lower  potency  of 
compound  3  was  found  analogously  effective  to 
inhibit  growth  of  the  fungal  strains  with  MIC  4 
￿g/￿L for Aspergillus fumagatus, Penicillium and 
MIC  determined  for  Aspergillus  Niger  was  8 
￿g/￿L (Table 3).  The very high activity by means 
of  potency  of  calixarene  derivative  (3)  against 
most  of  the  bacterial  and  fungal  strains  revealed 
the high level of significance in this study, leading 
towards the future control  over infections caused 
by problem pathogens. Previously, the noticeable 
differences in MIC values for bacterial and fungal 
strains  were  recorded  but  present  study  revealed 
the  MIC  level  of  3  that  was  exceptionally 
simultaneous in action against bacterial and fungal 
strains  at  lower  concentration  excluding  one 
Staphylococcus albus (Table 3). 
 
 
Table  3.  Minimum  inhibitory  concentration  of  compound  3 
against bacterial and fungal strains. 
 
Disc Content (￿g)  Microbial 
Strains  10  20  40  60  80 100 120 140 160 180 
MIC 
￿g/￿L 
Gram Positive 
Staphylococcus 
albus 
+  +  +  + 
 
￿  ￿  ￿  ￿  ￿  ￿ 
 
16 
Streptococcus 
viridans  
 
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
Gram Negative 
Bacillus 
procynous  
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
 
04 
Enterobacter 
aerogenes  
+  +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  08 
Klebsiella 
aerogenous  
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
Escherichia 
coli  
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
Sallmonella   +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
Fungus 
Aspergillus 
Niger 
+  +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
 
08 
Aspergillus 
fumagatus  
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
Penicillium  
 
+  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  04 
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Conclusion  
 
New  calixarene  derivative  5,11,17,28-
tetrakismorpholinomethyl-25,26,27,28-tetrahydro-
xycalix[4]arene (3) was synthesized and screened 
for bioactivity. The results show that all the tested 
microorganisms  including  various  strains  from 
gram  positive,  gram  negative  and  fungi  were 
susceptible  to  compound  3.  Since,  compound  3 
showed better antimicrobial profile against most of 
the  bacterial  and  fungal  strains  therefore;  this 
compound would be extended to further analysis of 
bioavailability and toxicity. 
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